Compare abrdn Income Credit Strategies Fund (ACP) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Smith & Nephew plc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Smith & Nephew plc trades at $30.13 (market cap $12.73B). The key difference: Smith & Nephew plc is far larger — about 19.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | SNN | |
|---|---|---|
Market Cap | $656.21M | $12.73B |
Sector | Financials | Health |
52-Week High | $5.98 | $38.70 |
52-Week Low | $5.01 | $28.73 |
Dividend Yield | 17.78% | 2.57% |
Enterprise Value | — | $15.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Smith & Nephew (SNN) trades at $30.48, up 0.76% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $5.8B in 2024 to $6.2B in 2025 and net income margin expanding to 10.13%. Recent product launches in robotics and wound care demonstrate innovation momentum. Technical indicators show support at $30 and resistance at $31, with moving averages signaling bullish momentum.
SNN presents a mixed investment case with strong revenue growth and margin expansion offset by inconsistent earnings performance. The company's $500M share buyback and positive 2026 outlook provide support, but recent earnings misses and cautious analyst sentiment (68% hold rating) suggest near-term caution. Key risks include execution challenges and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
